We are pleased to participate in World Arthritis Day (past event)

World Arthritis Day, referred to as WAD, aims at increasing disease awareness and knowledge on rheumatological conditions around the world. Current estimates list more than 200 rheumatic and musculoskeletal diseases (RMD), but their burden is largely underestimated by the general population. Consequently, a large proportion of patients are either not diagnosed or wait for extended periods of time before consulting their healthcare professionals.

More than 100.000.000 people worldwide suffer from rheumatological symptoms. These symptoms directly impact the quality of life of the patients and their professional activity. The inability to work reduces individuals’ self-esteem and increases their dependence on social assistance, family and friends.

Medical education has for a long time considered RMDs as second priority conditions, which means that symptoms might go unnoticed, misdiagnosed, or mistreated if people don’t have access to rheumatologists, nurses, physical therapists, or other healthcare professionals specifically trained in the field of RMD. As a result, people living with a rheumatic or musculoskeletal disease often have to face their condition alone and are lacking information on their symptoms, diagnosis and treatment options.

World Arthritis Day is intended to raise awareness on the existence and impact of RMD worldwide. This Day is an opportunity for all communities around the world to come together and speak with one voice to bring the much-needed messages to all audiences.

Over the past 20 years, TRB Chemedica has focused its rheumatological activities on osteoarthritis, the most prevalent joint disorder especially in middle-aged and elderly people.

Learn more

We are pleased to announce our presence at CPHI CONGRESS 2022 (past event)

Every year, CPHI brings together over 100,000 pharmaceutical industry professionals from around the world in physical and online workshops for the purpose of networking and identifying business opportunities. This year’s event is expected to be one of the busiest yet with over 39,000 expected participants.

If you are planning to attend, do not miss the opportunity to visit our stand #41F52.
Please contact our team for more information or to schedule a meeting onsite.

Celebrating 20 years of healthcare excellence in the United Kingdom!

We are proud to announce the 20th anniversary of TRB UK! Responsible for marketing our rheumatology and ophthalmology product ranges in the UK and Ireland since 2002, TRB UK is an ISO 9001 certified company, an achievement that demonstrates our commitment to patients and healthcare professionals and our dedication to quality.

VISIT THE WEBSITE

The benefits of hyaluronic acid in high impact sports

We are glad to welcome you at TRB’s Isokinetic Conference Workshop on Saturday June 4, 2022, to discuss the benefits of hyaluronic acid in high impact sports. The workshop will focus on early osteoarthritis in athletes and hyaluronic acid in tendinopathies. Join us in Lyon to learn more about these topics and exchange with our panel of speakers.

Workshop Program

ISOKINETIC MEDICAL GROUP CONFERENCE WORKSHOP

Saturday, 4 June 2022, 16:30-18:00, Room Bellecour 3

Learn more

Come visit us in Lyon at the Isokinetic Conference from 4th-6th June 2022 (past event)

We invite you to come visit our booth n°29/30 in Lyon at the Isokinetic Conference from 4th-6th June 2022. From relieving tendinopathy to accelerating post-arthroscopy recovery, we will be happy to share our expertise in relevant and exciting fields at this landmark event in Football Medicine & Orthopaedic Rehabilitation.

Learn more

Come visit us in Philadelphia from May 17th-19th at the CPhI North America 2022 (past event)

Come visit us from May 17th-19th at the CPhI North America 2022! We will be sharing our 40 years of experience in developing, producing, and promoting APIs, pharmaceutical products, and medical devices at this unique end-to-end pharma event in #Philadelphia.

We look forward to meeting and exchanging with you on-site or through the CPhI’s online platform.

CPhI North America

Let’s meet again in Milan at the CPHI Worldwide from November 9 to 11, 2021 at our stand n°3K101 (past event)

TRB Chemedica International will be present at the CPHI Worldwide Congress in Milan. Our team will be happy to welcome you on our booth. If you can’t make it, then let’s connect via the CPHI online platform which will be live from October 25 to November 19.

Event info

6th International Symposium on Intra-Articular Treatment in Krakov, 7-9 October (past event)

TRB Chemedica is pleased to invite you to the 6th International Symposium on Intra-Articular Treatment (ISIAT). We will be happy to meet you on our exhibition booth n°9.

Learn more

Watch the video of the conference “L’homme cérébral” that took place on March 13, 2021 (past event)

Magnoglia, TRB’s subsidiary in Monaco, was the main sponsor of the fully digital neuroscience conference “L’homme cérébral” that took place on March 13, 2021. This event was organised by the Fondation pour l’Étude du Système Nerveux (FESN) and focused on the theme “Memory”.

Watch the conference in English

Watch the conference in French

Strong scientific presence of TRB at WCO IOF-ESCEO virtual congress 2020 (past event)

TRB is pleased to support the first 100% virtual WCO-IOF-ESCEO e-congress which will take place from August 20 to 22 and available online until November 20, 2020. We are waiting for your visit at our booth in the virtual exhibition area!

TRB is also proud to host a Satellite Symposium entitled “Hyaluronic acid efficacy in osteoarthritis: beyond standard clinical parameters” which will be available online until November 20, 2020. This Symposium, chaired by Prof. Jean-Yves Reginster, University of Liège, will focus on the use of additional endpoints in clinical trials evaluating the efficacy of intra-articular hyaluronic acid such as our Ostenil products in osteoarthritis.

In addition, two posters summarising post-hoc analyses of TRB-sponsored clinical trials will be presented during the congress. Dr. Maheu, APHP Hôpital St-Antoine, Paris, will present the results of a post-hoc analysis of OSTP-EUR-10-01, a study published last December in PLoS One. This analysis compares the various definitions of responders that can be used in osteoarthritis (PASS, OMERACT-OARSI, MCII) and aimed at identifying predictive factors of a better response following intra-articular injection of hyaluronic acid.

The second poster is focusing on diacerein, a symptomatic slow-acting drug for osteoarthritis (SYSADOA). Prof. Jean-Pierre Pelletier, University of Montréal Hospital Research Centre, will discuss a post-hoc analysis of the DISSCO trial (A multicentre study on the effect of DIacerein on Structure and Symptoms versus Celecoxib in Osteoarthritis) aimed at exploring the influence of patient age on the magnitude of response to treatment with diacerein. Data revealed no differences between the efficacy and safety profile of diacerein in knee osteoarthritis patients younger or older than 65 years of age.

We are looking forward to participating in the first virtual WCO-IOF-ESCEO congress and hope that you share our excitement!

Visit the virtual congress